Stratification analysis showed that rs13293512 CC genotype was associated with an increased risk of BC in patients with negative estrogen receptor (adjusted OR = 2.39; 95% CI: 1.32-4.30; <i>P=</i>0.004), patients with negative progesterone receptor (adjusted OR = 1.92; 95% CI: 1.11-3.33; <i>P=</i>0.02), patients with T1-2 stage cancer (adjusted OR = 1.77; 95% CI: 1.07-2.93; <i>P=</i>0.03), and patients with N1-3 stage cancer (adjusted OR = 1.89; 95% CI: 1.13-3.17; <i>P=</i>0.015).